Ποια είναι η τιμή για MYUNGMOON Pharm co.,Ltd (017180)

Η τιμή για MYUNGMOON Pharm co.,Ltd (017180) είναι $0.84154769

Ποια είναι η κεφαλαιοποίηση αγοράς για MYUNGMOON Pharm co.,Ltd (017180)

Η κεφαλαιοποίηση αγοράς για MYUNGMOON Pharm co.,Ltd (017180) είναι $28.13M

MYUNGMOON Pharm co.,Ltd (017180) Τιμή και Κεφαλαιοποίηση Αγοράς

MYUNGMOON Pharm Co., Ltd. operates as a pharmaceutical enterprise, comprehensively handling the research, development, production, distribution, and commercialization of medicinal products. Its business activities extend across South Korea and into global markets. The company offers an extensive array of prescription drugs, addressing a broad spectrum of medical conditions. This range includes treatments for musculoskeletal issues like osteoarthritis, inflammation, rheumatoid arthritis, and muscle relaxation, alongside anti-infectives (antibiotics and antifungals), respiratory aids, and gastrointestinal therapeutics. Cardiovascular health is targeted with circulation agents, anti-hypertensive drugs, and antidiabetic medications. Furthermore, their specialized pharmacotherapy solutions cover narcotics, anesthetics, central nervous system agents, female hormone products, osteoporosis treatments, urogenital medications, adrenocortical hormones, oncology drugs, dermal fillers, and anti-obesity agents. Beyond prescription items, MYUNGMOON Pharm also supplies a diverse selection of over-the-counter (OTC) remedies. These encompass medications for nausea, genitourinary concerns, gum disease, liver support, parasitic infections, constipation, oral ailments, diarrhea, and general digestive health. The OTC portfolio further includes cold and flu treatments, calcium supplements, nasal sprays, multi-vitamins, eye nutrition products, eye drops, blood circulation enhancers, and topical preparations such as external skin treatments and localized pain relievers. In addition to its pharmaceutical lines, the firm markets health supplements, quasi-pharmaceuticals, and blended juice beverages. Established in 1983, MYUNGMOON Pharm Co., Ltd. maintains its primary corporate office in Seoul, South Korea.

Η τιμή για 017180	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$158,564 $28.13M	NVDA	$5.301T	+18,841,803.07%
$138,612 $28.13M	AAPL	$4.634T	+16,470,955.99%
$123,928 $28.13M	GOOG	$4.143T	+14,726,100.07%
$107,368 $28.13M	MSFT	$3.589T	+12,758,303.68%
$85,459.22 $28.13M	AMZN	$2.857T	+10,154,906.58%

Η τιμή για 017180

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$158,564 $28.13M